Recently a number of randomized trials have shown that treatment of patients with advanced colorectal cancer (CRC) do not benefit from therapies targeting the epidermal growth factor receptor (EGFR) when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes [1], [2], [3]. Here, EGFR is linked to colorectal carcinoma.